MIGENIX INC. -and- PACIFIC CORPORATE TRUST COMPANYWarrant Indenture • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations
For value received, the undersigned holder of Warrants hereby irrevocably sells, assigns and transfers unto the following transferees __________ Warrants of MIGENIX Inc. represented by the attached Warrant Certificate:
ContractTechnology Partnership Agreement • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations
The Company has requested confidential treatment with respect to certain portions of this Agreement, which have been omitted, pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AGENCY AGREEMENTAgency Agreement • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations • British Columbia
The Issuer proposes to raise funds for the purposes set forth in the Prospectus (as defined in this Agreement), which is to be filed by the Issuer with the Commissions (as defined in this Agreement) by offering for sale certain of its securities;
PATENT LICENSE AGREEMENT WITH RESEARCH COMPONENT BETWEEN UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. AND APOLLO BIOPHARMACEUTICS, INC. FEBRUARY 4, 1999Patent License Agreement • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations • Florida
This Agreement is made and entered into this 15th day of December 1993 (the Effective Date), and revised and restated on the 4th day of February 1999, by and between THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., a not-for-profit corporation duly organized and existing under the laws of the State of Florida and having its principal office at 223 Grinter Hall, Gainesville, Florida; 32611-2037, U.S.A. (hereinafter referred to UFRFI), and APOLLO BIOPHARMACEUTICS, INC., a corporation duly organized under the laws of the State of Delaware add having its principal office at One Broadway, Suite 600, Cambridge, Massachusetts 02142 (hereinafter referred to as LICENSEE).
ContractExclusive License Agreement • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations • Missouri
The Company has requested confidential treatment with respect to certain portions of this Agreement, which have been omitted, pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
MATERIAL TRANSFER AND LICENSE OPTION AGREEMENTMaterial Transfer and License Option Agreement • October 31st, 2005 • MIGENIX Inc. • Pharmaceutical preparations • New Jersey
This Material Transfer Agreement (the “Agreement”) is made as of July 13th, 2005 (the “Effective Date”), by and between Migenix Inc., a corporation having its principal offices at 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2 Canada (“Migenix”), and Schering Corporation, a New Jersey corporation, having offices at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (“Schering”).
